Published in Vaccine Weekly, November 7th, 2001
DynPort, a private company, is chartered with providing an integrated approach for the advanced development of specific vaccines and other products to protect against the threat of biological warfare agents. In 1997, the U.S. Department of Defense initiated the Joint Vaccine Acquisition Program, which includes a 10-year contract with DVC for the development of vaccines...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly